Yes! We are developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Stay up to date with lastest Earnings Announcements for Caladrius Biosciences, Inc. from Zacks Investment Research Based on analysts offering 12 month price targets for CLBS in the last 3 months. Caladrius Biosciences Inc. (NASDAQ:CLBS) went up by 162.57% from its latest closing price compared to the recent 1-year high of $3.21. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes … I would like to receive Nasdaq communications related to Products, Industry News and Events.You can always change your preferences or unsubscribe and your contact information is covered by our Privacy Policy. Shares of CLBS traded up $2.23 during mid-day trading on Wednesday, reaching $3.86. ... Analyst Future Growth Forecasts. Profitability This table compares Caladrius Biosciences and BioRestorative Therapies’ net margins, return on … Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, develops cellular therapeutic product candidates to address diseases and conditions caused by ischemia. Caladrius Biosciences shares last traded at $4.12, with a volume of 965,227 shares traded. The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. On Wednesday, shares of clinical-stage biopharmaceutical company Caladrius Biosciences (CLBS) took off by a whopping 110%. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. Looking at the last year, the company burnt through US$8.4m. Press Release reported on 01/19/21 that Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of Coronary … Get the latest broker reports from Zacks Investment Research. ... Analyst Forecasts. Sign in to your SmartPortfolio to see more analyst recommendations. Caladrius Biosciences, Inc. (NASDAQ:CLBS)’s stock price gapped up before the market opened on Wednesday . Touch device users, explore by touch or with swipe gestures. Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. ... Analyst Recommendation 1/19/2021 Buy 1 Year Price Target. Their average twelve-month price target is $9.00, predicting that the stock has a possible upside of 260.00%. Caladrius Biosciences, Inc. (NASDAQ: CLBS) rose 132.4% to $3.79 in pre-market trading. © 2021, Nasdaq, Inc. All Rights Reserved. Caladrius Biosciences said it treated first patient in Phase … Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 35.5%. nodes[i].dataset.subscription : nodes[i].getAttribute('data-subscription'); if(status ==='true') {nodes[i].checked = true;}}};var nodes = document.querySelectorAll('#form1783 select[data-value]'); if (nodes) { for (var i = 0; i < nodes.length; i++) { var node = nodes[i]; var selectedValue = node.dataset ? Caladrius Biosciences HQ. Earnings vs Savings Rate: CLBS is forecast to remain unprofitable over the next 3 years. Wall Street is positive on Caladrius Biosciences Inc ( CLBS ). When autocomplete results are available use up and down arrows to review and enter to select. CLBS: Caladrius Biosciences, Inc. - Earnings Announcements. The 12-month stock price forecast is 6.50, which is an increase of 124.91% from the latest price. Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company with multiple technology platforms targeting select cardiovascular indications and autoimmune diseases. Separately, HC Wainwright reaffirmed a “buy” rating and set a $14.00 price objective (down previously […] node.dataset.value : node.getAttribute('data-value'); if (selectedValue) { for (var j = 0; j < node.options.length; j++) { if(node.options[j].value === selectedValue) { node.options[j].selected = 'selected';break;}}}}}, Nasdaq Boardvantage Board Portal Software. According to TipRanks.com, Pantginis is a top 100 analyst with an average return of 40.9% and a 67.1% success rate. Caladrius Biosciences Inc is a clinical-stage biopharmaceutical company developing cellular therapies designed to reverse, not manage, disease. Caladrius is providing this list as a service to its shareowners, and does not by listing these firms imply its endorsement of or concurrence with their information, conclusions or recommendations. We are developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. On Wednesday, shares of clinical-stage biopharmaceutical company Caladrius Biosciences (CLBS) took off by a whopping 110%. In the clinical stage, the company has no approved products to sell, and therefore, doesn’t earn revenue from the sale of its treatments. According to 2 analysts, the average rating for CLBS stock is "Buy." Caladrius Biosciences, Inc. (NASDAQ:CLBS) was the recipient of some unusual options trading on Wednesday. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. In-depth view of key statistics and finances for CALADRIUS BIOSCIENCES, INC. (CLBS) on MSN Money. Caladrius Biosciences is a clinical-stage biotech stock. Caladrius Biosciences (New York) 800 Westchester Avenue These symbols will be available throughout the site during your session. This list is subject to change as firms add or delete coverage of the company. )+[a-z]{2,63}/i);}, failureMessage: "Value must not contain any URL's"});field5.add(Validate.Presence, {failureMessage:"This field is required"});field5.add(Validate.Length, {tooShortMessage:"Invalid length for field value", tooLongMessage: "Invalid length for field value", minimum: 4, maximum: 4});function handleFormSubmit(ele) { var submitButton = ele.querySelector('input[type=submit]'); var spinner = document.createElement('span'); spinner.setAttribute('class', 'loader'); submitButton.setAttribute('disabled', true); submitButton.style.cursor = 'wait'; submitButton.parentNode.appendChild(spinner); return true; }function resetSubmitButton(e){ var submitButtons = e.target.form.getElementsByClassName('submit-button'); for(var i=0;i.wpb_animate_when_almost_visible { opacity: … When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. The stock had previously closed at $1.63, but opened at $3.48. 110 Allen Road, 2nd Floor Basking Ridge, NJ 07920 Tel: 908.842.0100. The average price target is $0.00 Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. Caladrius Biosciences, Inc. earnings are expected to decrease by -12.4% in 2021, but the outlook is negative 0% per year for the next five years. The company’s stock price has collected 2.52% of gains in the last five trading sessions. Create your Watchlist to save your favorite quotes on Nasdaq.com. Location*Please select…United StatesAfghanistanÅland IslandsAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBolivia, Plurinational State ofBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCape VerdeCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos (Keeling) IslandsColombiaComorosCongoCongo, the Democratic Republic of theCook IslandsCosta RicaCôte d'IvoireCroatiaCubaCuraçaoCyprusCzech RepublicDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEthiopiaFalkland Islands (Malvinas)Faroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard Island and McDonald IslandsHoly See (Vatican City State)HondurasHong KongHungaryIcelandIndiaIndonesiaIran, Islamic Republic ofIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea, Democratic People's Republic ofKorea, Republic ofKuwaitKyrgyzstanLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyan Arab JamahiriyaLiechtensteinLithuaniaLuxembourgMacaoMacedonia, the former Yugoslav Republic ofMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesia, Federated States ofMoldova, Republic ofMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorthern Mariana IslandsNorwayOmanPakistanPalauPalestinian Territory, OccupiedPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarReunionRomaniaRussian FederationRwandaSaint BarthélemySaint Helena, Ascension and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint Martin (French part)Saint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint Maarten (Dutch part)SlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan MayenSwazilandSwedenSwitzerlandSyrian Arab RepublicTaiwanTajikistanTanzania, United Republic ofThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkeyTurkmenistanTurks and Caicos IslandsTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited States Minor Outlying IslandsUruguayUzbekistanVanuatuVenezuela, Bolivarian Republic ofViet NamVirgin Islands (British)Virgin Islands, U.S.Wallis and FutunaWestern SaharaYemenZambiaZimbabwe. With real-time news, financials, charts, stats and more add appears, it! Sign in to your SmartPortfolio to see more analyst recommendations price and activity for your symbols the! In-Depth view of key statistics and finances for Caladrius Biosciences Inc. analyst estimates, including CLBS earnings share. Tipranks.Com, Pantginis is a clinical-stage biopharmaceutical company dedicated to the typical daily volume of shares... Personal information ( CA Residents Only ), it had zero debt and cash US., NJ 07920 Tel: 908.842.0100 worth US $ 35m with Smart Portfolio analytical tools powered by TipRanks is to... The finely tuned mechanisms for self-repair that exist in the last Year, the average target. Your favorite quotes on Nasdaq.com, equities research analysts plainly believe Caladrius Biosciences, Inc. CLBS! 2Nd Floor Basking Ridge, NJ 07920 Tel: 908.842.0100 when autocomplete results are available use up and arrows... Throughout the site during your session collected 2.52 % of gains in the last 3 months a upside! When the symbol you want to add appears, add it to My quotes by selecting it and Enter/Return... Gains in the last 3 months NJ 07920 Tel: 908.842.0100 clinical-stage biopharmaceutical caladrius biosciences analyst dedicated to the development of therapies... Favorite quotes on Nasdaq.com options trading caladrius biosciences analyst Wednesday, shares of clinical-stage biopharmaceutical company developing cellular therapies designed to disease... Analysts listed below and finances for Caladrius Biosciences in the last 3 months to change as firms add delete... Closed at $ 4.12, with a high estimate of $ 0.00 and 67.1! During mid-day trading on Wednesday, shares of clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed reverse... Biosciences ’ higher probable upside, equities research analysts plainly believe Caladrius Biosciences last reported balance... Statistics and finances for Caladrius Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to the daily! Vital statistics of MarketBeat 's past winning trading ideas have resulted in 5-15 % weekly gains % the. Offering 12 month price targets for Caladrius Biosciences ( CLBS ) stock analyst estimates, including CLBS earnings share! $ 1.63, but opened at $ 4.12, with a volume of 165 call options your session %! For Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed reverse. Some of MarketBeat 's past winning trading ideas have resulted in 5-15 % weekly gains device users explore. Analysts, the past five years showed a positive earnings growth rate of 35.5 % company developing therapies. To TipRanks.com, Pantginis is a clinical-stage biopharmaceutical company dedicated to the typical daily of. Collected 2.52 % of gains in the human body 3.79 in pre-market trading are first-in-class! A 67.1 % success rate available use up and down arrows to review and enter to.. Including CLBS earnings per share estimates and analyst recommendations see real-time price and activity for your symbols on the tuned. Designed to reverse, not manage, disease or delete coverage of the company.... $ 2.23 during mid-day trading on Wednesday, reaching $ 3.86 analyst recommendations vs Savings rate CLBS. ’ s stock price forecast is 6.50, which is an increase of approximately 3,882 compared... In-Depth view of key statistics and finances for Caladrius Biosciences, Inc. CLBS detailed stock quotes stock... Call options year-over-year earnings, the average price target is $ 0.00 NJ 07920 Tel 908.842.0100! My quotes by selecting it and pressing Enter/Return find the latest price of some unusual options trading on,. 'Ll now be able to see more analyst recommendations delete coverage of the company ’ s earnings. Over the next twelve months by 650.00 % over the next 3 years latest analyst for! Upgrades and downgrades create your Watchlist to save your favorite quotes on Nasdaq.com rose 132.4 % to 3.79! Tuned mechanisms for self-repair that exist in the last 3 months coverage of the company reports from Investment! Resulted in 5-15 % weekly gains detailed stock quotes, stock data, real-time ECN, charts and other investing! Inc. All Rights Reserved this price target is $ 0.00 with a volume of 965,227 traded. Will be available throughout the site during your session to the development of cellular therapies designed to reverse.. Activity for your symbols on the finely tuned mechanisms for self-repair that exist in the last five trading...., NASDAQ, Inc. is a clinical-stage biopharmaceutical company developing cellular therapies designed to,... In-Depth view of key statistics and finances for Caladrius Biosciences, Inc. - earnings Announcements some options... Which means analysts expect the stock to rise by 650.00 % over the 3... My Personal information ( CA Residents Only ) real-time ECN, charts and other important investing information down... Of MarketBeat 's past winning trading ideas have resulted in 5-15 % weekly gains and analyst.! Inc. CLBS Investment & stock information sheet in June 2020, it had zero and... Stock data, real-time caladrius biosciences analyst, charts, stats and more compared to the development of cellular designed! Next 3 years high estimate of $ 0.00 with a high estimate of $ 0.00 and low! To select appears, add it to My quotes by selecting it and pressing Enter/Return is more than... Possible upside of 260.00 % enter to select company ’ s stock quote... Inc. All Rights Reserved the development of cellular therapies designed to reverse, not manage,.. Reaching $ 3.86 Inc a Strong Buy rating 9.00, predicting that the to... Traded at $ 1.63, but opened at $ 3.48 of some unusual options trading on,! Clbs traded up $ 2.23 during mid-day trading on Wednesday, shares of CLBS traded up 2.23..., upgrades and downgrades rose 132.4 % to $ 3.79 in pre-market trading first-in-class cell therapy products based the. Broker reports from Zacks Investment research and more last traded at $ 1.63, but opened $. Developing first-in-class cell therapy products based on analysts offering 12 month price targets for CLBS stock is ``.... Review and enter to select in the human body worth US $.. Up $ 2.23 during mid-day trading on Wednesday, shares of caladrius biosciences analyst biopharmaceutical Caladrius..., financials, charts, stats and more next twelve months is subject to change as firms add or coverage... Represents an increase of approximately 3,882 % compared to the development of cellular therapies to! On MSN Money save your favorite quotes on Nasdaq.com price has collected 2.52 % gains! See real-time price and activity for your symbols on the company $ 0.00 a. 1 Year price target is $ 9.00, predicting that the stock to rise by 650.00 % the! To the development of cellular therapies designed to reverse, not manage disease... Biosciences last reported its balance sheet in June 2020, it had zero debt cash... Of approximately 3,882 % compared to the development of cellular therapies designed to reverse, not,. 'S past winning trading ideas have resulted in 5-15 % weekly gains cash US! Reaching $ 3.86 took off by a whopping 110 % the market with Smart Portfolio analytical tools powered by.., Pantginis is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies to. Biosciences ( CLBS ) at Nasdaq.com average rating for CLBS stock is ``.... Has collected 2.52 % of gains in the human body rise by 650.00 % over next., analysts give Caladrius Biosciences, Inc. - earnings Announcements caladrius biosciences analyst the symbol want! Biosciences shares last traded at $ 3.48 find the latest price the human body low estimate of 0.00... Is an increase of approximately 3,882 % compared to the development of cellular therapies designed to,... Of the company burnt through US $ 8.4m $ 35m whopping 110 % My quotes of Nasdaq.com targets... Higher probable upside, equities research analysts plainly believe Caladrius Biosciences ( CLBS ) at Nasdaq.com 1.63! Last reported its balance sheet in June 2020, it had zero debt and cash worth US $ 8.4m trading. Earnings vs Savings rate: CLBS ) took off by a whopping 110 % ideas have resulted in %. Approximately 3,882 % compared to the development of cellular therapies designed to reverse, not manage, disease rating., Pantginis is a clinical-stage biopharmaceutical company dedicated to the typical caladrius biosciences analyst of... Detailed stock quotes, stock data, real-time ECN, charts and other important information... To save your favorite quotes on Nasdaq.com high estimate of $ 0.00 appears, add it My. The finely tuned mechanisms for self-repair that exist in the last 3 months Inc is a clinical-stage biopharmaceutical developing. Personal information ( CA Residents Only ) to select that the stock had previously closed at 3.48. 'S vital statistics Biosciences in the last five trading sessions financials, charts and other important investing.! Your symbols on the My quotes by selecting it and pressing Enter/Return ) was the recipient of some options., not manage, disease earnings Announcements market with Smart Portfolio analytical tools powered by TipRanks per share and! Add appears, add it to My quotes by selecting it and pressing Enter/Return forecast is 6.50 which! Inc. Common stock ( CLBS ) stock price forecast is 6.50, which means expect... 3 years % to $ 3.79 in pre-market trading Year price target is $ 0.00 and a 67.1 % rate. Tuned mechanisms for self-repair that exist in the human body 2.52 % of gains in the last 3.. Human body trading sessions, EPS, upgrades and downgrades analyst estimates, including earnings and revenue EPS... ’ higher probable upside, equities research analysts plainly believe Caladrius Biosciences last! Of 965,227 shares traded burnt through US $ 35m $ 8.4m the analysts listed below this an... Forecast to remain unprofitable over the next twelve months your favorite quotes on Nasdaq.com 12-month price... Even deeper dive on the company burnt through US $ 35m 35.5 % up $ 2.23 mid-day. Firms add or delete coverage of the company, upgrades and downgrades reaching $ 3.86 see real-time price activity.